6-K
Haleon plc (HLN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2025
Commission File Number: 001-41411
Haleon plc
(Translation of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form<br>20-F ☒ | Form<br>40-F ☐ |
|---|
EXHIBIT INDEX
| Exhibit Number | Description |
|---|---|
| 99.1 | 05<br>September 2025 - “Director/PDMR<br>Shareholding” |
99.1
Haleon plc: Director/PDMR Shareholding
5 September 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
This notification sets out the details of the grant of Haleon share awards over Ordinary Shares and American Depositary Shares (ADS) made to PDMRs under the Haleon Share Value Plan and Performance Share Plan.
The Performance Share Plan (Interim) awards are subject to continued employment and performance conditions over the performance period ending on 31 December 2027 (vesting in March 2028). Performance targets were disclosed in the Annual Report and Form 20-F 2024.
The Share Value Plan (Buyout) awards are subject to continued employment.
All awards were made in line with the principles of Haleon's Directors' Remuneration Policy and are subject to malus and clawback provisions.
| 1 | Details of the person discharging managerial responsibilities /<br>person closely associated | ||
|---|---|---|---|
| a) | Name | Carl<br>Haney | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief<br>R&D Officer | |
| b) | Initial notification /Amendment | Initial<br>Notification | |
| 3 | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction<br>monitor | ||
| a) | Name | Haleon<br>plc | |
| b) | LEI | 549300PSB3WWEODCUP19 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | ||
| a) | Description of the financial instrument, type of<br>instrument<br><br><br><br><br><br>Identification<br>code | Ordinary Shares of 0.01 each<br><br> <br><br><br>GB00BMX86B70 | |
| b) | Nature of the transaction | (i) Grant<br>of a conditional award under the Haleon plc Performance Share Plan<br>(Interim)<br><br> <br><br>(ii) Grant<br>of a conditional award under the Haleon plc Share Value Plan<br>(Buyout) | |
| c) | Price(s) and volume(s) | Volume(s) | |
| (i) | 641,096 | ||
| (ii) | 192,571 | ||
| d) | Aggregated information<br><br><br><br><br><br>-<br>Aggregated volume<br><br><br><br><br><br>- Price | 833,667<br><br> <br><br><br>Nil | |
| e) | Date of the transaction | 4<br>September 2025 | |
| f) | Place of the transaction | Outside a trading venue |
All values are in British Pounds.
| 1 | Details of the person discharging managerial responsibilities /<br>person closely associated | |||
|---|---|---|---|---|
| a) | Name | Nathalie Gerschtein | ||
| 2 | Reason for the notification | |||
| a) | Position/status | President<br>North America | ||
| b) | Initial notification /Amendment | Initial<br>Notification | ||
| 3 | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction<br>monitor | |||
| a) | Name | Haleon<br>plc | ||
| b) | LEI | 549300PSB3WWEODCUP19 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | |||
| a) | Description of the financial instrument, type of<br>instrument<br><br><br><br><br><br>Identification<br>code | Haleon plc American Depositary Shares (ADS)<br><br><br><br><br><br>US4055521003 | ||
| b) | Nature of the transaction | (i) Grant<br>of a conditional award under the Haleon plc Performance Share Plan<br>(Interim)<br><br><br><br><br><br>(ii) Grant<br>of a conditional award under the Haleon plc Share Value Plan<br>(Buyout) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| (i) | Nil | 244,400 | ||
| (ii) | Nil | 405,911 | ||
| d) | Aggregated information<br><br><br><br><br><br>-<br>Aggregated volume<br><br><br><br><br><br>- Price | 650,311<br><br><br><br><br><br>Nil | ||
| e) | Date of the transaction | 4<br>September 2025 | ||
| f) | Place of the transaction | Outside a trading venue |
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HALEON PLC<br><br><br>(Registrant) | |||
|---|---|---|---|
| Date: September 05,<br>2025 | By: | /s/<br>Amanda Mellor | |
| Name: | Amanda<br>Mellor | ||
| Title: | Company<br>Secretary |